Omecamtiv Mecarbil

Summary

Omecamtiv Mecarbil (CHEMBL1800955) is a phase-3 clinical-stage small molecule (ATC C01CX10); indicated across 2 conditions including heart failure and cardiovascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01CX10
• Indications: 2 conditions
• Clinical trials: 11
• Chemistry: 401.4 Da · C20H24FN5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1800955
Name	Omecamtiv Mecarbil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11689883
ATC	C01CX10
Molecular formula	C20H24FN5O3
Molecular weight	401.4
InChIKey	RFUBTTPMWSKEIW-UHFFFAOYSA-N

SMILES: CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC

IUPAC name: methyl 4-[[2-fluoro-3-[(6-methyl-3-pyridinyl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate

Also known as: CK-1827452, Omecamtiv mecarbil, Omecamtiv mecarbilo, OMECAMTIV MECARBIL, SID174007336, OMECAMTIV MECARBIL (CK-1827452), Omecamtiv Mecarbil, Omecamtiv mecarbilÊ, Omecamtiv mecarbil (CK-1827452), Omecamtiv mecarbilÂ

Patent coverage: 215 distinct patent families (673 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 601 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
heart failure	3	MONDO:0005252	EFO:0003144
cardiovascular disorder	3	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	3
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02929329	PHASE3	COMPLETED	Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
NCT03759392	PHASE3	COMPLETED	Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
NCT04464525	PHASE3	WITHDRAWN	Omecamtiv Mecarbil Post-trial Access Study
NCT00624442	PHASE2	COMPLETED	A Study of CK-1827452 Infusion in Stable Heart Failure
NCT00748579	PHASE2	TERMINATED	Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
NCT00941681	PHASE2	COMPLETED	Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
NCT01077167	PHASE2	WITHDRAWN	Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
NCT01300013	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
NCT02695420	PHASE2	COMPLETED	Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
NCT01380223	PHASE1	COMPLETED	A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
NCT02601001	PHASE1	COMPLETED	Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).